CORRECTING and REPLACING: Theraclion Strengthens Its Board of Directors
22 Giugno 2021 - 10:05PM
Business Wire
Regulatory News:
This replaces the announcement made at 6:00 pm CET on June 22,
2021 due to updates to the 2nd paragraph relating to investment
from Bernard Sabrier and Unigestion acting on their own behalf and
3rd paragraph relating to Mehdi El Glaoui's investment
motivation.
Theraclion
Strengthens Its Board of Directors
THERACLION (Paris:ALTHE) (ISIN: FR0010120402; Memo: ALTHE,
PEA-PME eligible), an innovative company specializing in ultrasound
therapy (using High Intensity Focused Ultrasound or HIFU),
announces the arrival of a health specialist, Mehdi El Glaoui. He
joins the board of directors and also invests 1.5% of the company's
capital.
Two weeks after the announcement that Bernard Sabrier and
Unigestion, acting on their own behalf, had crossed thresholds in
Theraclion’s shareholding, Mehdi El Glaoui, known for his success
in healthtech, decided to invest and join the company's board.
"Theraclion offers very interesting development potential. Beyond
its technology, which can transform the surgical gesture, the
combination of imaging and robotization with artificial
intelligence can propel the company much further in terms of
treatments and development." states Mehdi El Glaoui.
Mehdi El Glaoui was convinced of the company's value creation.
He decided to personally participate in Theraclion's future.
"Mehdi El Glaoui, brings us the expertise and vision to take our
company from an innovative medtech model to a truly disruptive
healthtech company. Theraclion will then be truly positioned to
transform the world of healthcare. Mehdi understands that our
ultrasound platform has potential far beyond the treatment of
thyroid, breast and varicose veins. The developments he supports,
accelerate our innovation for exponential growth." said David
Caumartin, CEO of Theraclion.
About Mehdi El Glaoui
Swiss resident since 2008, Mehdi El Glaoui is a Doctor of
Pharmacy from the Faculty of Pharmacy of Paris V (1980), Associate
Professor of Public Health at the Faculty of Medicine of Liège
(2001-2007). He was Chairman and CEO of Cassenne Laboratories
(1987-1996) and Wyeth Laboratories (1997-2007). He became Chairman
of Louis Dreyfus Commodities in Geneva (2009-2012), then board
member as of 2012. In 2011, he founded Majorelle International, a
company specialized in the development of pharmaceutical products
in Gynecology and Urology. Majorelle International has sold 60% of
its French subsidiary Laboratoires Majorelle in 2021 to the
American fund EW Healthcare Partners.
About Theraclion
Theraclion has developed an innovative echotherapy solution
using High Intensity Focused Ultrasound for the treatment of
varicose veins, SONOVEIN®. The treatment solution, which obtained
CE marking in April 2019, is based on the leading-edge echotherapy
treatment expertise developed by Theraclion over years for
non-invasive ablation of breast fibroadenomas and thyroid nodules
using its ECHOPULSE® solution. Further improvements to the
ECHOPULSE technology are the foundation for SONOVEIN to provide the
only non-invasive ablation therapy for varicose veins. This
procedure allows for treatment without a catheter, chemical
injection, or incision. An operating room is not necessary, and the
treatment can be performed at a doctor’s offices or in clinics, as
well as in hospitals. Venous pathology is widespread worldwide and
generates around 5 million treatment procedures per year, according
to Millennium research Varicose Vein Device Market Study 2015.
Theraclion's technological solutions are based on high-tech
ultrasound medical devices that are precise and easy to use for
practitioners.
Located in Malakoff, near Paris, Theraclion brings together a
team of 25 people, more than half of whom are dedicated to R&D
and clinical trials.
For more information, please visit the Theraclion website:
www.theraclion.com and the patient site:
https://echotherapie.com/echotherapy/
Theraclion is listed on Euronext Growth Paris Eligible for the
PEA-PME scheme Mnemonic: ALTHE - ISIN code: FR0010120402 LEI:
9695007X7HA7A1GCYD29
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210622006046/en/
Theraclion David Caumartin Chief Executive Officer
david.caumartin@theraclion.com Tel : + 33 (0)1 55 48 90 70
Anja Kleber VP Marketing, Market Access & Sales Francophonia
anja.kleber@theraclion.com
Grafico Azioni Theraclion (EU:ALTHE)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Theraclion (EU:ALTHE)
Storico
Da Apr 2023 a Apr 2024